Register for Upcoming Webinar on DEC. 8 @ 11AM
2026 China NMPA Bluebook is here:
China’s Point of Care Testing industry: A billion-dollar market and growing 20-30% annually The rapid growth of the Point of Care Testing Industry and the obvious
China’s In Vitro Diagnosis (IVD) Market is an opportunity for U.S. companies to take their product offering overseas. Here is a current overview of the
EYE TECH CARE, a French medical device company, has received approval from CFDA to begin marketing its EyeOP1® glaucoma treatment product in China. The first
China Med Device cordially invites you to our latest regulatory event in Boston on December 10th, 2017 and the opportunity to meet face to face
The 2017 China BioMed Innovation and Investment Conference (2017 CBIIC) was held in Suzhou China lately. It was co-hosted by Securities Association of China (SAC),
CryoLife, a US-based medical device and tissue processing company focused on cardiac and vascular surgery, announced that enrollment has started in the company’s BioGlue clinical
CFDA just released a Solicitation for Public Comments (SPC) for its proposed amendment of the Medical Device Regulations (MDR), as mandated by a recent order
According to a recent market study conducted in China, over a third of Chinese adults are now suffering from high blood pressure. To make matters
On October 8th, China State Council released guidelines for Further Reform Registration Reviewing and Approval to encourage medical device/drug innovation for comments. The guidelines contain
On October 10th, the CFDA released a new notice about “The Related Work for Regulating the Medical Device Classification.” Here are the highlights: 1. For
On October 20th, CFDA released the new technical requirements for accepting overseas clinical data for comments. This technical requirement is based on the guidelines from
On October 31st, the CFDA released and implemented the 3rd batch of “Medical Device Clinical Trial Exemption List”. There are 37 Class II, 11 Class